ENTX - エンテラ・バイオ (Entera Bio Ltd.) エンテラ・バイオ

 ENTXのチャート


 ENTXの企業情報

symbol ENTx
会社名 Entera Bio Ltd (エンテラ・バイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism osteoporosis and bone healing.  エンテラ・バイオはイスラエルのバイオ医薬品企業。有効な治療法が確立されていない疾患のための治療薬の発見、開発および商品化に焦点を当て事業を行う。主に副甲状腺機能低下症および骨粗しょう症の治療薬として経口カプセルの開発を手掛ける。主要製品候補には、副甲状腺ホルモンの治療薬EB612や、骨粗しょう症および癒着不能骨折の治療薬EB613などがある。   Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
本社所在地 Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem 9112002 ISR
代表者氏名 Gerald M. Lieberman ジェラルド・M・リーバーマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号
設立年月日 40330
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.enterabio.com
nasdaq_url https://www.nasdaq.com/symbol/entx
adr_tso
EBITDA EBITDA(百万ドル) -12.65700
終値(lastsale) 5.85
時価総額(marketcap) 66855672
時価総額 時価総額(百万ドル) 60.11296
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 88.47196
当期純利益 当期純利益(百万ドル) -10.02400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Entera Bio Ltd revenues was not reported. Net loss decreased 31% to $2.6M. Lower net loss reflects FV Adjustments of Financial Investments increase from $479K to $2.9M (income) GENERAL AND ADMINISTRATIVE EXPENSES (INC decrease of 70% to $854K (expense) Other financial expenses (income) net increase from $71K (expense) to $23K (income).

 ENTXのテクニカル分析


 ENTXのニュース

   Entera Bio''s (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript  2022/03/08 16:09:08 Seeking Alpha
   Entera Bio GAAP EPS of -$0.47 beats by $0.58, revenue of $0.57M beats by $0.03M  2022/03/08 11:44:08 Seeking Alpha
Entera Bio press release (ENTX): FY GAAP EPS of -$0.47 beats by $0.58.Revenue of $0.57M (+54.1% Y/Y) beats by $0.03M.
   Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX)  2021/11/21 07:24:42 Transcript Daily
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []
   Kodiak Sciences (NASDAQ:KOD) & Entera Bio (NASDAQ:ENTX) Head-To-Head Review  2021/11/18 16:14:42 Dakota Financial News
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is []
   Entera Bio Ltd. (NASDAQ:ENTX) to Post FY2021 Earnings of ($0.77) Per Share, B. Riley Forecasts  2021/11/16 07:16:41 Dakota Financial News
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous []
   Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX)  2021/11/21 07:24:42 Transcript Daily
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []
   Kodiak Sciences (NASDAQ:KOD) & Entera Bio (NASDAQ:ENTX) Head-To-Head Review  2021/11/18 16:14:42 Dakota Financial News
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is []
   Entera Bio Ltd. (NASDAQ:ENTX) to Post FY2021 Earnings of ($0.77) Per Share, B. Riley Forecasts  2021/11/16 07:16:41 Dakota Financial News
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous []
   Entera Bio (NASDAQ:ENTX) Issues Earnings Results, Beats Estimates By $0.03 EPS  2021/11/12 00:42:42 Transcript Daily
Entera Bio (NASDAQ:ENTX) released its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts consensus estimates of ($0.12) by $0.03, Fidelity Earnings reports. Entera Bio had a negative return on equity of 161.80% and a negative net margin of 3,414.71%. Entera Bio stock traded up $0.02 []
   Entera Bio reports 9M results  2021/11/10 13:43:02 Seeking Alpha
   Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX)  2021/11/21 07:24:42 Transcript Daily
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []
   Kodiak Sciences (NASDAQ:KOD) & Entera Bio (NASDAQ:ENTX) Head-To-Head Review  2021/11/18 16:14:42 Dakota Financial News
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is []
   Entera Bio Ltd. (NASDAQ:ENTX) to Post FY2021 Earnings of ($0.77) Per Share, B. Riley Forecasts  2021/11/16 07:16:41 Dakota Financial News
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous []
   Entera Bio (NASDAQ:ENTX) Issues Earnings Results, Beats Estimates By $0.03 EPS  2021/11/12 00:42:42 Transcript Daily
Entera Bio (NASDAQ:ENTX) released its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts consensus estimates of ($0.12) by $0.03, Fidelity Earnings reports. Entera Bio had a negative return on equity of 161.80% and a negative net margin of 3,414.71%. Entera Bio stock traded up $0.02 []
   Entera Bio reports 9M results  2021/11/10 13:43:02 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エンテラ・バイオ ENTX Entera Bio Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)